A second-generation version of afami-cel has shown promise in a clinical trialExit Disclaimer involving people with various types of cancer, including esophageal cancer. The therapy, known as uza-cel, also targets MAGE-A4Exit Disclaimer. âThis work demonstrates the feasibility of conducting cutting-edge research with new treatment approaches in rare diseases, such as synovial sarcoma,â Dr. DâAngelo said. The demonstration that T-cell receptor therapy can treat solid tumors âis an important See more